Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1988 Aug;85(15):5659-63.
doi: 10.1073/pnas.85.15.5659.

T-cell epitopes in Pf155/RESA, a major candidate for a Plasmodium falciparum malaria vaccine

Affiliations

T-cell epitopes in Pf155/RESA, a major candidate for a Plasmodium falciparum malaria vaccine

L Kabilan et al. Proc Natl Acad Sci U S A. 1988 Aug.

Erratum in

  • Proc Natl Acad Sci U S A 1988 Nov;85(22):8648

Abstract

Immunogens included in a subunit vaccine should contain both B- and T-cell-activating sites to ensure anamnestic responses following reinfection after vaccination as well as antibody-independent cellular immunity. The Plasmodium falciparum antigen Pf155/RESA, a major candidate for a vaccine against the asexual blood stages of this malaria parasite, was investigated for T-cell epitopes in its C-terminal amino acid repeat region, a region known to be conserved in different P. falciparum strains. It was found to contain several related sequences that activated T cells from humans primed to P. falciparum by natural exposure, to proliferation, and/or interferon-gamma release in vitro. T cells from approximately half of the donor group investigated responded to the intact protein, and 65% of these responders also responded to short synthetic peptides, probably representing a small number of partly overlapping T-cell epitopes. Thus, sequences from the C terminus of Pf155 may be suitable constituents of a P. falciparum subunit vaccine and also provide a basis for epitope-specific epidemiological studies relating cellular immune responses in vitro to clinical immunity and P. falciparum endemicity.

PubMed Disclaimer

References

    1. Scand J Immunol. 1976 Jun;Suppl 5:57-68 - PubMed
    1. Scand J Immunol. 1979;10(6):525-33 - PubMed
    1. Clin Exp Immunol. 1983 Aug;53(2):345-53 - PubMed
    1. J Exp Med. 1984 Jun 1;159(6):1686-704 - PubMed
    1. Nature. 1984 Aug 30-Sep 5;310(5980):789-92 - PubMed

Publication types

MeSH terms